Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14874MR)

This product GTTS-WQ14874MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14874MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4989MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ8350MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ3422MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ10284MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ6483MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ9572MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ5252MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW